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In pulmonary tuberculosis (TB), the inflammatory immune response against Mycobacte-
rium tuberculosis (Mtb) is associated with tissue destruction and cavitation, which drives 
disease transmission, chronic lung disease, and mortality. Matrix metalloproteinase 
(MMP)-1 is a host enzyme critical for the development of cavitation. MMP expression 
has been shown to be epigenetically regulated in other inflammatory diseases, but the 
importance of such mechanisms in Mtb-associated induction of MMP-1 is unknown. 
We investigated the role of changes in histone acetylation in Mtb-induced MMP expres-
sion using inhibitors of histone deacetylases (HDACs) and histone acetyltransferases 
(HAT), HDAC siRNA, promoter-reporter constructs, and chromatin immunoprecipitation 
assays. Mtb infection decreased Class I HDAC gene expression by over 50% in primary 
human monocyte-derived macrophages but not in normal human bronchial epithelial 
cells (NHBEs). Non-selective inhibition of HDAC activity decreased MMP-1/-3 expression 
by Mtb-stimulated macrophages and NHBEs, while class I HDAC inhibition increased 
MMP-1 secretion by Mtb-stimulated NHBEs. MMP-3 expression, but not MMP-1, was 
downregulated by siRNA silencing of HDAC1. Inhibition of HAT activity also significantly 
decreased MMP-1/-3 secretion by Mtb-infected macrophages. The MMP-1 promoter 
region between −2,001 and −2,942 base pairs from the transcriptional start site was key 
in control of Mtb-driven MMP-1 gene expression. Histone H3 and H4 acetylation and 
RNA Pol II binding in the MMP-1 promoter region were increased in stimulated NHBEs. In 
summary, epigenetic modification of histone acetylation via HDAC and HAT activity has a 
key regulatory role in Mtb-dependent gene expression and secretion of MMP-1 and -3, 
enzymes which drive human immunopathology. Manipulation of epigenetic regulatory 
mechanisms may have potential as a host-directed therapy to improve outcomes in the 
era of rising TB drug resistance.
Keywords: Mycobacterium tuberculosis, matrix metalloproteinases, histone deacetylases, histone 
acetyltransferases, epigenetics
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inTrODUcTiOn
Tuberculosis (TB) remains a major global health problem, with 
10.4 million new cases and 1.8 million deaths per year (1). The 
rapid emergence of widespread drug resistance necessitates new 
strategies to improve the efficacy of treatment in TB, both to 
decrease transmission and to improve patient outcomes. Ideally, 
such therapies will shorten the duration of therapy, which is 
currently a minimum of 6 months and may be years in drug-
resistant disease. Host-directed therapies are increasingly of 
interest in TB (2).
The primary site of Mycobacterium tuberculosis (Mtb) infec-
tion is the lung, and pulmonary disease is characterized by granu-
lomatous inflammation with destruction of lung parenchyma. 
The outcome of infection is very variable between hosts, and the 
factors determining this are not well understood, although host 
genetics and innate immune responses are important determi-
nants of disease (3, 4). Matrix metalloproteinases (MMPs) are 
zinc-dependent endopeptidases, which have key roles in tissue 
repair and in diseases characterized by inflammatory tissue 
destruction such as emphysema (5). MMPs are key mediators of 
inflammatory cell migration, and modulators of chemokine and 
cytokine signaling (6, 7). MMP activity is strongly implicated in 
the immunopathogenesis of TB. Our group and others demon-
strated the involvement of MMP-1, the major human collagenase, 
and its activator MMP-3 (stromelysin-1) in driving pathology 
in pulmonary TB (8–10). MMPs are secreted by Mtb-infected 
monocytes and macrophages, and also by uninfected stromal 
cells stimulated via intercellular networks (11). Epigenetic 
mechanisms are emerging as major regulators of MMP activity in 
non-infectious diseases (12, 13), including chronic lung diseases 
such as asthma and COPD (14), but their role in MMP expression 
in TB is less established.
Epigenetic regulation encompasses all chromosomal modifi-
cations that alter gene expression without altering the nucleotide 
sequence of coding DNA (15, 16). Eukaryotic DNA is packaged 
as chromatin around octamers of histone proteins, which contain 
globular domains and negatively charged tails. These are subject 
to extensive post-translational modification, including acetyla-
tion of highly conserved lysine residues. Acetylation of histones 
H3 and H4, carried out by Histone acetyltransferases (HATs), is 
associated with increased gene transcription (17). Conversely, 
acetyl groups are removed by the histone deacetylases (HDACs), 
which are divided into four classes. The Class I HDACs (1, 2, 
3, and 8) are ubiquitously expressed, whereas Class II HDACs 
(such as HDAC 4 and 5) are selectively expressed in different tis-
sues. HDAC activity is usually associated with silencing of gene 
expression (18, 19). However, this is not uniformly the case and 
opposite regulation may occur. For example, HDAC inhibition 
reduced MMP-9 gene expression in cancer cell lines resulting in 
a less invasive phenotype (20).
The epigenetic mechanisms regulating inflammatory immune 
responses in TB are an emerging field. Altered miRNA expression 
in serum and sputum from TB patients compared to controls has 
been shown, and potential biomarkers for diagnosis have been 
identified (21). A growing body of evidence exists to support 
the importance of epigenetic mechanisms in other respiratory 
infections, for example, altered DNA methylation patterns in 
asthma patients versus healthy controls have been implicated in 
the pathogenesis of rhinovirus infection (22). Similarly, altered 
DNA (cytosine-5-)-methyltransferase-1 (DMT-1) expression in 
nasal epithelial cells from smokers was identified as a possible 
mechanism of increased susceptibility to influenza (23). In vitro 
studies of airway epithelial cells demonstrated increased HDAC2 
expression and decreased histone acetylation in respiratory 
syncytial virus (RSV)-infected cells, while chemical HDAC inhi-
bition restricted RSV replication (24). In the current study, we 
have investigated whether epigenetic modifications, specifically 
histone acetylation/deacetylation, regulated the characteristic 
TB-associated expression of MMP-1 and MMP-3 by monocyte-
derived macrophages and normal human bronchial epithelial 
cells (NHBEs), thereby augmenting TB immunopathology. The 
role of histone acetylation in induction of MMP-1/-3 expression 
was specifically investigated, since this dynamic epigenetic mark 
is associated with transcriptional activation. We demonstrate that 
Mtb infection alters macrophage Class I HDAC expression and 
that MMP-1 expression induced by Mtb is sensitive to HDAC/
HAT inhibition. In addition, increased histone acetylation was 
seen at MMP-1 and -3 promoter regions compared with unstimu-
lated cells, specifically in the region −2,001 to −2,942 bp of the 
MMP-1 promoter, which contains key inducible sites activated in 
Mtb-stimulated cells.
MaTerials anD MeThODs
reagents and antibodies
Trichostatin A (TSA) was purchased from Sigma-Aldrich (Gillingham, 
UK), CBHA, HAT inhibitor II and Anacardic acid (AA) from 
Calbiochem (Millipore, Watford, UK), and MS-275 from Enzo Life 
Sciences (Exeter, UK). Primary rabbit anti-human acetyl-histone H3 
and acetyl-histone H4 (Millipore) were used for chromatin immuno-
precipitation. Primary mouse anti-human HDAC4 and anti-HDAC7 
were used for Western blot and HRP-linked goat anti-rabbit IgG and 
goat anti-mouse (all from Cell Signalling, Hertfordshire, UK) were 
used as secondary antibodies. All other reagents were purchased from 
Sigma-Aldrich unless otherwise stated.
Mtb culture
Mycobacterium tuberculosis strain H37Rv was cultured from 
frozen stocks stored at −80°C in Middlebrook 7H9 broth (BD 
Biosciences, Oxford, UK) supplemented with 10% OADC enrich-
ment medium (BD Biosciences), 0.2% glycerol, and 0.02% Tween 
20 with agitation at 37°C. Growth was monitored by measuring 
optical density (OD) using a Biowave cell density meter (WPA, 
Cambridge, UK). Infection experiments were performed using 
cultures at mid-log growth (at OD 0.55–0.65) corresponding to 
1–2 × 108 CFU/ml. Correlation with optical density was checked 
by performing colony counts in triplicate on Middlebrook 7H11 
agar. Cells were infected at a multiplicity of infection (MOI) of 1 
unless otherwise stated.
cell culture
Monocytes were adhesion-purified from leukocyte residues from 
healthy blood donors (NHS Blood Transfusion Service) and 
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differentiated into macrophages for 4 days in RPMI 1640 (Life 
Technologies, Paisley, UK) supplemented with 10% fetal bovine 
serum (FBS) and 100 ng/ml M-CSF (R&D Systems, Abingdon, 
UK). After a further 24  h without M-CSF, the medium was 
changed for M-SFM (Life Technologies) and cells were infected 
with Mtb H37Rv strain. Cells were pretreated with chemical 
inhibitors for 2 h prior to infection where relevant.
Primary NHBEs (Lonza, Wokingham, UK) were cultured 
according to the supplier’s instructions in supplemented bron-
chial epithelial growth medium (BEGM). Medium was replaced 
every 3 days. Cells were subcultured at 80% confluence and used 
at passage 4 or 5.
The alveolar carcinoma cell line A549 (ATCC, Middlesex, UK) 
was cultured in RPMI 1640 supplemented with 2 mM glutamine, 
10 µg/ml ampicillin, and 10% FBS. For experiments, cells were 
seeded at 4 × 104 cells/cm2 and stimulated 24 h later.
conditioned Medium from Mycobacterium 
tuberculosis-infected Monocytes (coMTb)
Peripheral blood monocytes isolated as above from healthy 
blood donors were infected with H37Rv at a MOI of 1 in RPMI 
without FBS for 24  h. The culture medium was then collected 
and sterilized by passage through a 0.2  µM Anopore syringe 
filter (Whatman, Brentford, UK). Paired samples of conditioned 
medium from uninfected monocytes (CoMCont) from the same 
donor were used as controls.
MMP elisas
Supernatants were collected at 72 h poststimulus, sterile filtered, 
and MMPs were quantified using the Duoset MMP-1 and MMP-3 
ELISA kits (R&D Systems) according to manufacturer’s instruc-
tions. Lower limits of sensitivity for the Duoset kits are: 156 pg/
ml for MMP-1 and 31.2  pg/ml for MMP-3. Samples were run 
with appropriate controls and at dilutions calculated to give 
readings within the linear range of detection as indicated by the 
manufacturer.
luminex Multiplex immunoassay
Quantification of MMP-1, -3, -7, and -9 concentrations was 
performed using the Fluorokine MultiAnalyte Profiling MMP 
Base Kit (R&D Systems) and the Luminex platform Bio-Plex 200 
(Bio-Rad, Hemel Hempstead, UK) dual laser analyzer. Standard 
curves were generated using Bio-Plex Manager version 5.0. 
Lower limits of sensitivity for the Fluorokine Luminex were: 
1.1  pg/ml for MMP-1, 7.3  pg/ml for MMP-3, 6.6  pg/ml for 
MMP-7, and 13.7 pg/ml for MMP-9. All samples were run with 
appropriate controls and were within the linear range of detection 
as indicated by the manufacturer.
Western Blotting
Cells were washed in PBS and scraped and homogenized in lysis 
buffer (62.5 mM Tris, 2% SDS, 10% glycerol, 50 mM DDT with 
bromophenol blue) prior to storage at −80°C. Samples were 
denatured by heating to 90°C for 5 min and loaded on 4–12% 
NuPAGE Bis-Tris mini gels (Life Technologies) and run at 200 V 
for 70–90  min. Proteins were transferred to a nitrocellulose 
membrane (GE Healthcare) at 4°C, 30 V, for 1 h before block-
ing with 5% skimmed milk protein/TBS/0.1% Tween 20 buffer 
and incubating with diluted primary antibody. Membranes 
were incubated with diluted HRP-linked secondary antibody 
and developed using ECL Prime developing kit (GE Healthcare, 
Hatfield, UK).
Transient Transfection with Promoter-
reporter constructs
MMP-1 promoter constructs expressed in the pGL3 firefly 
(Photinus pyralis) luciferase expression vector (Promega, South-
ampton, UK) were a gift of Professor Ian Clark (University of East 
Anglia, Norwich, UK). The full-length wild-type (WT) MMP-1 
pro moter construct (WT) comprised a 4,372  bp sequence 
upstream of the MMP-1 transcriptional start site. Deletion con-
structs ranged in size from 3,830 to 517 bp (25). MMP-3 promoter 
constructs were designed in-house and cloned into the pGL3 vec-
tor. Truncations were generated using primers that incorporated 
restriction enzyme sites within the sequence of interest: MMP3-1R 
5′-GCTTTACTTAGATCTATGTTGTCTC-3′; MMP3-4F 5′-GC 
TAGAGCTAGCAAGGATCCTGCAC-3′; MMP3-6R 5′-CTTCA 
TTTCCACAAGCTTTACTTAGCTCT-3′; MMP3-7F 5′-GTTTT 
CCTCCTCGAGAACCAGCAAATCC-3′; MMP3-8F 5′-CATCA 
TTCTACTGAGCTCTTACTCCCAAG-3′; MMP3-9F 5′-CCATG 
TCTGTAATCCTAGCACTTTGAG-3′; MMP3-10F 5′-GTTCAG 
TGTGGAAAATAGAGTAGCAGAGG-3′; MMP3-11—F 5′-GA 
TGGATTCTCGAGTTCAACTTCAAAGCATCTG-3′; MMP3-
12—R 5′-GAGACAGAGATCTCACTATGTTGCCC-3′. PCR 
products of the 3 kb MMP-3 promoter region were digested in 
one step using NheI and BglII, followed by BamHI and BglII 
for cloning into pGL4 and pBSK vectors. Shorter fragments of 
the original 3kb MMP-3 promoter region were digested using 
HindIII and XhoI for MMP3-7F/MMP3-6R; SacI and HindIII for 
MMP3-8F/MMP3-6R and MMP3-9F/MMP3-6R, and KpnI and 
HindIII for MMP3-10F/MMP3-6R. After 2 h incubation at 37°C, 
enzymes were inactivated at 68°C for 20  min. The constructs 
generated were 2,183, 1,612, and 642 bp in length. WT MMP-1/-3 
promoters and respective truncations were inserted upstream of 
the luciferase reporter gene in the pGL3 vector. The PRL-TK 
plasmid constitutively expressing Renilla luciferase was used to 
control for transfection efficiency.
A549 cells were transfected when 60% confluent with FuGene 
6 (Roche, Lewes, UK), and 0.8 µg plasmid DNA or control plas-
mid DNA. Sixteen hours after transfection, the cells were stimu-
lated according to the experimental conditions. Twenty-four 
hours later, cells were washed once in PBS and lysed in passive 
lysis buffer (Promega). Luciferase assays were performed using 
the Promega Dual-Luciferase Reporter Assay kit (Promega) 
using an L-Max 2 luminometer (Molecular Devices, Sunnydale, 
CA, USA).
real-time Pcr
After 24  h incubation in the specified experimental settings, 
cells were lysed in TRI-reagent and total RNA extracted with the 
PureLink RNA mini kit (Life Technologies) with on-column DNase 
treatment. RNA concentrations and purity were evaluated using 
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a Nanodrop spectrophotometer (Thermo Scientific, Wilmington, 
DE, USA). A total of 1 µg of sample RNA was reverse transcribed 
using the Quantitect RT Kit (Qiagen, Crawley, UK) according to 
the manufacturer’s instructions. Real-time PCR was performed 
using Brilliant II qPCR mastermix (Agilent, UK) on a Stratagene 
Mx3000p platform (Stratagene, La Jolla, USA). The thermal pro-
file was 10 min at 95°C, followed by 40–45 cycles of 30 s at 95°C 
and 1 min at 60°C. The cycle threshold (Ct) at which amplification 
entered the exponential phase was determined for each well and 
analyte. 18S ribosomal RNA, β-actin, and GAPDH RNA were 
used as reference genes. The following primers and probes were 
used to analyze target and reference genes.
MMP-1 forward primer 5′-AAGATGAAAGGTGGACCAAC 
AATT-3′; reverse primer 5′-CCAAGAGAATGGCCGAGTTC-3′ 
and probe 5′-FAM CAGAGAGTACAACTTACATC GTGTTG 
CGGCTC-TAMRA-3′; GAPDH forward primer 5′-CGCTTCG 
CTCTCTGCTCC T-3′; reverse primer 5′-CGACCAAATCCGT 
TGACTCC-3′ and probe 5′-HEX-CGTCGCC AGCCGAGC 
CACAT-TAMRA-3′ (both from Sigma-Aldrich); MMP-3 
Hs00968305_m1; HDAC1 Hs02621185_s1; HDAC2 Hs00231032_
m1; HDAC3 Hs0018730_m1; HDAC4 Hs01041638_m1; HDAC5 
Hs00608366_m1; HDAC8 Hs00218503_m1; 18S 4308329 and 
β-actin 431088E (all Taqman primer and probe mixes from Life 
Technologies). Cts from target genes were normalized to Cts for 
the reference genes that were measured simultaneously for each 
PCR assay performed.
Transfection of epithelial cells with sirna
ON-TARGETplus SMARTpool siRNA oligonucleotides and 
transfection reagents were purchased from Dharmacon (Thermo 
Scientific). NHBEs were cultured in complete medium and 
transfected at 60–70% confluence. siRNA and Lipofectamine 
2000 were diluted in Optimem and used at final concentrations 
of 30  nM and 25  µg/ml, respectively. After 4  h, each well was 
washed with PBS and fresh BEGM was added. The cells were 
then rested overnight prior to stimulation with the experimental 
conditions. For analysis of mRNA expression, cells were lysed and 
total RNA was extracted 24 h after stimulation. For analysis of 
protein expression, cell culture supernatants were collected for 
ELISA and cells were washed in PBS and lysed in Western lysis 
buffer 48 h poststimulation.
chromatin immunoprecipitation assay 
(chiP)
Magna-ChIP kits and antibodies were purchased from Millipore 
(Watford, UK) and used according to manufacturer’s instructions. 
The rabbit polyclonal anti-acetyl-Histone H4 antibody was raised 
against tetra acetylated H4 and recognizes intermediately acety-
lated H4, but not acetylation on lysine 16. The rabbit polyclonal 
anti-acetyl-Histone 3 antibody was raised against acetylated 
N-terminus of H3.
Cells were cultured in 100 or 150 mm tissue culture dishes until 
confluent then stimulated as previously described. Cells were fixed 
with fresh 1% paraformaldehyde solution for 10 min and the reac-
tion was stopped with glycine. Chromatin was sheared by sonica-
tion with a Covaris S2 ultra-sonicator using an Adaptive Focused 
Acoustics intensifier (KBioscience). Settings were as follows: 
temperature 6–8°C, duty cycle 20%, intensity 8, 200 cycles/burst, 
15 cycles of 30 s, 2 × 107 cell equivalents/ml. Immunoprecipitation 
was performed overnight at 4°C with 1 × 106 cell equivalents per 
condition. Purified DNA was eluted and PCR performed using 
SYBR Green JumpStart Taq Readymix. Reactions were performed 
in triplicate on the Stratagene Mx3000P platform (Stratagene, 
La Jolla, USA). The following custom unlabeled primers were 
designed in-house and supplied by Sigma. MMP-1 transcrip-
tion start site forward primer 5′-TGGGATATTGGAGCAGC 
AAG-3′and reverse primer 5′-AGCTGTGCATACTGGCCT 
TT-3′ (product size 82 bp); -500 bp MMP-1 promoter forward 
primer 5′-TAAGGGAAGCCAT GGTGCTA-3′; reverse primer 
5′-AGGTTCCCTTCTGCCTTTGT-3′ (product size 65  bp); 
−2  kbp MMP-1 promoter forward primer 5′TTGCCAGATG 
GGACAGTGTA-3′ and reverse 5′-TCAGGAAAGCAGCAT 
GTGAC-3′ (product size 123  bp); −4  kbp MMP-1 promoter 
forward primer 5′-CTTGAGGCCAGGAGTTTGAG-3′ and 
reverse primer 5′-ACCACCAT GTCCCACTGATT-3′ (product 
size 89 bp).
These assays were not performed in technical triplicates due to 
the number of cells required per condition.
statistics
Unless otherwise stated, results shown are from experiments 
performed in triplicate and representative of at least two inde-
pendent experiments. Comparisons between two groups were 
made using the Student’s t-test (two-tailed with significance set 
as p < 0.05). For comparison of three or more groups, one-way 
ANOVA was used with Tukey’s correction for multiple com-
parisons. Unless otherwise stated in figure legends, graphs show 
mean values for triplicate samples and error bars are the SD.
resUlTs
class i hDacs are suppressed by Mtb 
infection of Macrophages
Experiments were designed to investigate epigenetic regulation of 
TB immunopathology, first investigating whether Mtb infection 
of macrophages altered Class I HDAC expression. Expression 
of Class I HDACs was repressed by Mtb infection, with a 68% 
decrease in HDAC1, 69% in HDAC2, 76% in HDAC3, and 58% 
in HDAC8 compared with uninfected controls (all p <  0.05) 
(Figures  1A–D). Next, we examined monocyte network-
dependent stimulation of NHBEs by CoMTb. In contrast to 
macrophage stimulation by Mtb, CoMTb stimulation of NHBEs 
did not significantly alter accumulation of any class I HDAC 
mRNAs (Figures 1E–H). Expression of Class II HDACs 4 and 
5 was also examined by RT-PCR. HDAC4 mRNA accumulation 
was increased by 48% in Mtb-infected macrophages, while no 
difference was observed for HDAC5 (Figures 1I,J). Increase in 
HDAC4 protein level was confirmed by western blot (Figure 
S1 in Supplementary Material). Class II HDAC expression in 
CoMTb-stimulated NHBEs was similar to control conditions 
(Figures 1K,L). Thus, exposure to live Mtb selectively suppressed 
macrophage class I HDAC expression.
FigUre 1 | class i histone deacetylase (hDac) expression is downregulated in Mycobacterium tuberculosis (Mtb)-infected macrophages. 
Macrophages were infected with H37Rv at a multiplicity of infection of 1, while normal human bronchial epithelial cells (NHBEs) were stimulated with CoMTb (1:5 
dilution), for 24 h before total RNA was extracted for Class I HDAC gene expression analysis. Figures show mRNA levels (AU) for: (a,e) HDAC1, (B,F) HDAC2,  
(c,g) HDAC3, (D,h) HDAC8 for macrophages and NHBEs, respectively. For Class II HDAC analysis, RNA was processed in a similar manner and figures show an 
(i,K) HDAC4 mRNA and (J,l) HDAC5 mRNA accumulation for macrophages and NHBEs. Bars represent mean ± SD and analysis was performed using Student’s 
t-test. *p < 0.05; **p < 0.01. AU, arbitrary units.
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non-selective hDac inhibition reduces 
MMP-1 and -3 expression in Macrophages 
and nhBes during Mtb infection
Next, we investigated whether histone acetylation status affected 
MMP expression using the non-selective HDAC inhibitor 
(HDACi) TSA. A total of 100  ng/ml TSA markedly decreased 
Mtb-stimulated MMP-1 and MMP-3 secretion by macrophages 
(Figures 2A,B). In NHBEs, TSA significantly decreased baseline 
MMP-1 secretion by over 50% (p <  0.05; Figure 2C). CoMTb-
stimulated MMP-1 secretion was decreased by TSA treatment, 
although this did not reach statistical significance (Figure 2C). In 
contrast, CoMTb-stimulated MMP-3 secretion was significantly 
reduced in a dose-dependent manner by 25% with 1  ng/ml 
TSA (from 2.4 to 1.8  ng/ml) and by 72% with 10  ng/ml TSA 
(685 pg/ml) (Figure 2D).
Further experiments were performed using an alternative 
chemical HDACi, CBHA (m-Carboxycinnamic Acid bis-
Hydroxamide), to confirm that the observed effects were due 
to HDAC inhibition and not non-specific. Pretreatment of 
macrophages with 4 µM CBHA before Mtb infection decreased 
MMP-1 secretion by 77% (from 8.89 to 2.05 ng/ml) and MMP-3 
secretion to undetectable levels (Figures 2E,F). CoMTb-driven 
MMP-1 secretion was reduced by CBHA treatment in a dose-
dependent manner. 5 µM CBHA reduced MMP-1 secretion by 
41% (from 797 to 473 pg/ml; p < 0.05; Figure 2G), while 1 µM 
FigUre 2 | continued
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FigUre 2 | continued  
Mycobacterium tuberculosis (Mtb)-driven matrix metalloproteinase (MMP)-1 and -3 secretion is suppressed by histone deacetylase (hDac) 
inhibition. Macrophages and normal human bronchial epithelial cells (NHBEs) were preincubated with 1–100 ng/ml trichostatin A (TSA) (a–D), 0.1–5 µM CBHA 
(e–h) or 1–10 µM MS-275 (i–l) to inhibit HDAC activity, prior to infection with H37Rv (multiplicity of infection 1) or stimulation with CoMTb (1:5 dilution) for 72 h, 
then MMP-1 and -3 secretion was measured. Pretreatment with TSA suppressed: (a) MMP-1 and (B) MMP-3 secretion from Mtb-infected macrophages. In 
CoMTb-stimulated NHBEs (c), MMP-1 secretion was unaltered and (D) MMP-3 secretion decreased with TSA treatment. Pretreatment with CBHA suppressed:  
(e) MMP-1 and (F) MMP-3 secretion from Mtb-infected macrophages and (g) MMP-1 and (h) MMP-3 secretion from CoMTb-stimulated NHBEs. The Class I 
selective HDACi MS-275 suppressed: (i) MMP-1 and (J) MMP-3 secretion from Mtb-infected macrophages, while it increased (K) MMP-1 secretion and decreased 
(l) MMP-3 secretion from CoMTb-stimulated NHBEs. Secretion of MMP-7 was not affected by (M) TSA and (n) 1 µM MS-275 treatment in Mtb-infected 
macrophages. Bars represent mean ± SD and analysis was performed using one-way ANOVA with Tukey’s posttest. *p < 0.05; **p < 0.01; ****p < 0.0001. CBHA, 
m-Carboxycinnamic Acid bis-Hydroxamide.
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CBHA was sufficient to completely inhibit CoMTb-induced 
MMP-3 secretion (p < 0.0001; Figure 2H). These results indicate 
that HDACs may differ between cell types, each with specific 
MMP regulatory pathways.
The HDAC class I-selective inhibitor MS-275 (1 µM) inhibited 
Mtb-driven macrophage MMP-1 secretion by 92% and reduced 
MMP-3 concentrations by 94.4% (Figures 2I,J). This supports the 
earlier finding and implies a key regulatory role for class I HDACs 
in macrophages MMP-1/-3 expression. In contrast, MS-275 
enhanced MMP-1 secretion by both unstimulated (p < 0.05) and 
CoMTb-stimulated NHBEs (p < 0.0001; Figure 2K). MS-275 at 
a low concentration of 1 µM increased MMP-3 secretion 4.6-fold 
compared to CoMTb alone (p < 0.05), but this was not observed 
at the higher concentration of 10 µM MS-275 (Figure 2L), pos-
sibly due to sublethal cell toxicity, which could not be detected by 
cell viability experiments. The effects of these HDACi on MMP 
secretion were selective, since neither TSA nor 1 µM MS-275 sig-
nificantly altered MMP-7 secretion by Mtb-infected macrophages 
(Figures 2M,N).
silencing hDac1 expression Does not 
affect coMTb-Driven MMP-1 expression
Next, we investigated whether a specific class I HDAC enzyme 
was necessary for CoMTb-induced MMP-1 and -3 expression. 
HDAC1 mRNA was reduced by more than 80% in CoMTb-
stimulated cells transfected with 30  nM HDAC1 siRNA com-
pared to non-targeting (NT) siRNA or untransfected controls 
(Figure  3A; p  =  0.001). Despite efficient HDAC1 silencing, 
no significant differences were observed in MMP-1 mRNA 
accumulation (Figure  3B). Consistent with this, MMP-1 con-
centrations were 3,204 pg/ml in CoMTb/HDAC1 siRNA treated 
samples compared to 3,746  pg/ml in the CoMTb/NT siRNA 
samples (Figure 3C). MMP-3 mRNA was upregulated threefold 
by CoMTb stimulation but no difference was observed between 
NT and HDAC1 siRNA-transfected NHBEs (Figure  3D). 
MMP-3 protein secretion in the NT-transfected cells was 
upregulated by CoMTb (p < 0.001), and MMP-3 secretion was 
reduced by 30% in HDAC1 siRNA-transfected cells compared 
to NT-transfected conditions (p < 0.01; Figure 3E). Silencing of 
HDAC2 in epithelial cells with siRNA (Figure 3F) was also effec-
tive and increased CoMTb-stimulated MMP-1, but not MMP-3, 
mRNA expression compared to CoMTb alone (p  <  0.05; 
Figures  3G,H). Silencing HDAC3 with siRNA did not affect 
MMP-1 or MMP-3 expression (Figures S2A–C in Supplementary 
Material).
Macrophage-Derived MMP-1 and -3 gene 
expression and secretion during Mtb 
infection are Blocked by haT inhibition
Next, the role of HAT activity was investigated using the inhibi-
tor HATi II. 10  µM HATi II significantly decreased MMP-1 
secretion from Mtb-infected macrophages by 56% (from 5,029 to 
2,187 pg/ml) and mRNA accumulation by 62% (Figures 4A,B). 
MMP-3 secretion was decreased from 1,653 to 190  pg/ml 
(p <  0.0001, Figure  4C). There was a non-significant trend to 
decreased MMP-3 mRNA accumulation with HATi II treatment 
(Figure 4D). HATi II treatment did not affect MMP-7 secretion in 
response to Mtb infection (Figure S3 in Supplementary Material).
A second HAT inhibitor, AA (10 µM), reduced Mtb-infected 
macrophage MMP-1 secretion by 74% (from 5,029 to 1,302 pg/ml; 
p  <  0.0001) (Figure  4E). Similarly, a significant decrease in 
MMP-1 secretion was also detected in stimulated NHBE cells 
pretreated with AA (Figure S4 in Supplementary Material). 
Secretion of MMP-3 in Mtb-infected macrophages was also 
inhibited by 10 µM AA (p < 0.01; Figure 4F). The AA compound 
is closely related to salicylic acid and has been reported to have 
some antimicrobial activity, including against Mtb (26, 27). We 
therefore investigated whether these results might be secondary 
to an effect on Mtb growth, but this was not altered in broth 
cultures containing AA at concentrations between 2 and 25 µM 
(Figure  4G). These experiments support the hypothesis that 
HAT activity is required for inducible expression of MMP-1 and 
MMP-3 in macrophages and NHBEs stimulated with Mtb.
MMP-1 and MMP-3 Promoter-reporter 
analysis in TB
Plasmid promoter-reporter constructs of the MMP-1 and MMP-3 
promoter regions were transfected into A549 respiratory epithe-
lial cells to investigate the effect of Mtb-stimulation on promoter 
activity. A schematic representation of the relevant region of the 
human MMP-1 promoter region is shown in Figure 5A. CoMTb 
treatment increased promoter activity of the WT construct by 
more than threefold compared to controls (p = 0.02; Figure 5B). 
CoMTb-mediated promoter activation was significantly 
enhanced by 98 and 71% in the 3,830 and 2,942 bp constructs, 
respectively, compared to CoMTb-stimulated WT (p <  0.01). 
Further truncation of the promoter resulted in loss of CoMTb-
driven promoter activity. The MMP-3 promoter, examined using 
similar methodology, showed a progressive reduction in both 
basal and CoMTb-stimulated promoter activity with truncation 
FigUre 3 | silencing of hDac1 and hDac2 expression does not inhibit coMTb-driven matrix metalloproteinase (MMP)-1 gene expression. Normal 
human bronchial epithelial cells (NHBEs) were transfected with 30 nM non-targeting (NT), HDAC1- or HDAC2-specific siRNA, or treated with transfection reagent 
alone. Cells were then stimulated with CoMTb (1:5) for 24 or 48 h. (a) HDAC1 mRNA normalized to the reference gene ACTB shows siRNA suppresses mRNA 
levels. (B) MMP-1 mRNA accumulation and (c) MMP-1 secretion following HDAC1 silencing are not significantly suppressed by siRNA. (D) MMP-3 mRNA 
accumulation remained unchanged, while (e) MMP-3 secretion decreased following HDAC1 silencing. (F) HDAC2 mRNA normalized to the reference gene ACTB 
and accumulation was silenced by HDAC2 siRNA. HDAC2 silencing increased MMP-1 mRNA accumulation (g) and did not affect MMP-3 mRNA accumulation  
(h) in CoMTb-stimulated NHBEs. mRNA of target genes was normalized to mRNA of the reference gene ACTB. Bars represent mean ± SD and analysis was 
performed using one-way ANOVA with Tukey’s posttest. *p < 0.05; **p < 0.01; ****p < 0.0001; ns, non-significant; ACTB, beta-actin; HDAC, histone deacetylase 
siRNA; NT, non-target siRNA.
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of the construct from 1,612 to 642 bp in length (Figure 5C) com-
pared to WT. The 1,612 bp truncation is missing a stromelysin 
platelet-derived growth factor responsive element (SPRE; −1,659 
to −1,643 bp) and part of the stromelysin IL-1 responsive element 
(−1,614 to −1,595 bp), and in addition, the 642 bp truncation is 
missing 4 AP-1, 2 STAT3, and 1 c-rel binding sites.
FigUre 4 |  haTi ii inhibits Mycobacterium tuberculosis (Mtb)-driven matrix metalloproteinase (MMP)-1 and -3 secretion. Macrophages were preincubated 
with 10 µM HATi II or 1–10 µM AA prior to infection with H37Rv (multiplicity of infection 1). Total RNA was extracted after 24 h and cell culture supernatants were 
collected after 72 h. Pre-treatment with the HATi II suppressed: (a) MMP-1 secretion and (B) MMP-1 mRNA accumulation, as well as (c) MMP-3 secretion and  
(D) MMP-3 mRNA accumulation. Pre-treatment with 1–10 µM AA suppressed: (e) MMP-1 and (F) MMP-3 secreted concentrations in Mtb-infected macrophages.  
(g) H37Rv was cultured in the presence of AA 2–25 µM and bacterial growth was accessed by optical density (OD) measurements. Bars represent mean ± SD and 
analysis was performed using one-way ANOVA with Tukey’s posttest. *p < 0.05; **p < 0.01; ****p < 0.0001; ns, non-significant; ACTB, beta-actin; AA, anacardic acid.
9
Moores et al. Epigenetic Regulation of MMPs in TB
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 602
FigUre 5 |  regulation of matrix metalloproteinase (MMP)-1 and -3 transcription in coMTb-stimulated respiratory epithelial cells. WT and truncations 
of the MMP-1 and MMP-3 promoters expressed in the pGL3 firefly luciferase expression vectors were transfected into A549 cells. MMP-1 and -3 promoter activity 
for each truncation was assessed by relative luciferase activity compared to WT controls. (a) Schematic representation of WT MMP-1 promoter and truncations and 
relevant transcription factors binding sites. (B) MMP-1 promoter activity is significantly repressed in truncations upstream −2,001 bp of the transcriptional start site. 
(c) MMP-3 promoter activity is suppressed by truncations upstream −1,612 bp from the transcriptional start site. Bars represent mean ± SD and analysis was 
performed using one-way ANOVA with Tukey’s posttest. *p < 0.05; **p < 0.01; ***p < 0.001. AU, arbitrary unit; WT, wild-type.
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FigUre 6 | Mycobacterium tuberculosis (Mtb)-driven matrix 
metalloproteinase (MMP)-1 expression is associated with increased 
rna Pol ii binding and increased histone h3 and h4 acetylation of the 
MMP-1 promoter. ChIP assays were performed on normal human bronchial 
epithelial cells treated with CoMTb (black triangles) or control medium (gray 
circles) for 1 h (dashed line) or 2 h (solid line) poststimulation. (a) RNA Pol II, 
(B) acetylated histone H3, and (c) acetylated histone H4 association with the 
MMP-1 promoter increases after 2 h CoMTb stimulation, particularly between 
−2,000 to −1,000 bp from the transcriptional start site. Data presented as 
percentage of the total chromatin input (% input) and figures are 
representative of three independent experiments. Acetyl H3, acetylated 
histone H3; Acetyl H4, acetylated histone H4; ChIP, chromatin 
immunoprecipitation; RNA Pol II, RNA polymerase II.
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coMTb-Driven MMP-1 expression and 
increased histone acetylation in the 
Promoter region
To further investigate whether epigenetic modifications of 
the MMP-1 promoter controlled the response to CoMTb, we 
examined the histone acetylation status of the MMP-1 promoter 
region by chromatin immunoprecipitation. Preliminary experi-
ments using the respiratory epithelial A549 cell line suggested 
marked increases in histone H4 acetylation with CoMTb treat-
ment at 1 and 2  h poststimulus (data not shown). In primary 
NHBEs, RNA Polymerase II binding to the MMP-1 promoter 
was increased between 10- and 15-fold in cells after 2  h of 
CoMTb treatment (Figure  6A). Histone H3 acetylation was 
increased 2 h poststimulation and was approximately threefold 
greater than under control conditions in the proximal promoter, 
and fivefold higher than control when measured 2 kbp upstream 
of the MMP-1 transcriptional start site (Figure 6B). Detection 
of acetylated histone H4 after 2  h of CoMTb stimulation was 
also increased across the MMP-1 promoter region. Histone H4 
acetylation was 10-fold higher at −2 kbp and −500 bp, and 6-fold 
higher than unstimulated controls at the transcriptional start site 
(Figure 6C).
DiscUssiOn
Upregulation of MMP-1 in TB is a critical event for the develop-
ment of cavitation (9). Previous studies from our group and other 
have demonstrated that Mtb-stimulation upregulates MMP-1 
expression, which is enzymatically active and able to degrade type 
I collagen, the main component of the lung’s ECM [Al (10, 28, 29)]. 
Expression of other MMPs is also induced in pulmonary TB 
(28, 30), and MMPs are implicated in central nervous system 
immunopathology (31, 32). In this study, we demonstrated that 
expression of MMP-1 and -3 in response to Mtb is controlled by 
epigenetic changes in histone acetylation. HDACs are canonically 
considered to be negative regulators of gene expression, and we 
showed a change in the profile of HDAC expression following 
Mtb infection of macrophages. Downregulation of Class I HDAC 
gene expression was observed with a concomitant and selective 
upregulation of HDAC4 but not HDAC5. In contrast, in respira-
tory epithelial cells, Class I and Class II HDAC expression were 
unchanged after CoMTb stimulation, implying that this is a cell 
type-specific effect. TLR signaling is known to induce changes in 
HDAC expression and activity (33), and our findings are consist-
ent with published evidence of selective changes in macrophage 
HDAC expression in response to specific inflammatory stimuli 
(34). Our data show that Mtb infection of macrophages induces 
a change in the cellular HDAC profile. We went on to investigate 
the likely effects of this change by performing experiments in 
which MMP responses were examined under conditions of both 
general and specific HDAC blockade.
Non-selective HDAC inhibition using TSA and the bipolar 
hybrid CBHA suppressed Mtb-driven MMP-1 and -3 secre-
tion and mRNA accumulation in primary epithelial cells and 
macrophages. Such a paradoxical effect on MMP expression has 
been previously reported in an in vitro model of arthritis, where 
chondrocyte collagenase activity was inhibited by TSA (35). In 
a mouse model of arthritis, TSA also inhibited MMP-1, -3, and 
-13 expression (36). Similarly, LPS-induced MMP expression 
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by murine bone marrow-derived macrophages was inhibited by 
TSA (37). The Class I selective HDACi MS-275 had contrast-
ing effects: increasing basal and CoMTb-stimulated MMP-1 
and -3 secretion in epithelial cells, while in Mtb-infected mac-
rophages, it decreased MMP-1/-3 secretion. Similar inhibition 
of cytokine-induced MMP-1 was seen in MS-275 treated human 
chondrocytes (38). The effects of MS-275 may be due to selective 
inhibition of HDAC1 at lower concentrations, and additional 
effects on the activity of HDAC2 and 3 at higher concentrations 
(39). Individual HDAC enzymes are likely to play different roles 
in regulation of MMP expression, and since these chemicals 
affect function of multiple HDACs, it is impossible to dissect 
the relative contribution of each HDAC by a chemical inhibition 
approach alone.
The increased secretion of MMP-1 and -3 from NHBEs 
observed with Class I HDAC inhibition, as compared to non-
selective HDAC inhibition, is consistent with the premise that 
Class I HDACs are key negative regulators of MMP expression. 
HDAC1 was shown to be recruited to the MMP-9 promoter 
site, reducing histone H3 acetylation and NF-κB recruitment, 
leading to repression of MMP-9 expression in fibrosarcoma 
cells (40).
The enhancement of CoMTb-stimulated MMP expression 
observed with MS-275 led us to hypothesize that silencing the 
expression of HDAC1 might similarly increase inducible MMP 
expression. The catalytic activity of HDAC 1 and 2 is reliant 
on their incorporation as heterodimers into multiprotein 
assemblies (41) and therefore we expected that silencing either 
HDAC 1 or HDAC 2 would affect MMP expression. However, in 
spite of a high efficiency of HDAC1 silencing, MMP-1 expres-
sion was unaffected, and MMP-3 secretion was decreased in 
HDAC1-silenced cells. In contrast, upregulation of MMP-1 
in CoMTb-stimulated conditions was further enhanced with 
HDAC2 inhibition, suggesting that MS-275 could be having 
its effect via inhibition of HDAC2 rather than HDAC1. The 
differing results for HDAC1 and HDAC2 silencing are unex-
pected given the close homology between these proteins, and 
consequently further dissection of their relative contributions 
to control of MMP expression is needed. In other experimental 
systems, different HDACs have been implicated in MMP 
regulation and there may be cell and stimulus specificity in 
host responses. In synovial fibroblasts from arthritis patients, 
HDAC1 siRNA enhanced TNFα-induced MMP-1 expression 
(42), whereas HDAC4 was identified as a negative regulator of 
MMP-1 expression (43).
Consistent with the hypothesis that epigenetic modifications 
regulate MMP secretion in TB, expression of MMP-1 and -3 were 
both suppressed by HAT inhibition with HATi II. Experiments 
using a structurally unrelated HAT inhibitor, AA, generated con-
sistent data. Similarly, in human dermal fibroblasts exposed to UV 
light, AA inhibited MMP-1 expression, as did siRNA silencing of 
p300 expression. Increased HAT activity and histone H3 acetyla-
tion and decreased HDAC activity preceded changes in MMP-1 
gene expression (44). The finding that both HAT and HDAC 
inhibition decreased MMP-1 and -3 expression, while apparently 
contradictory, may reflect the complex interdependence of these 
processes. It is well recognized that many non-histone substrates 
of these enzymes exist (45, 46) and indeed phylogenetic studies 
have indicated that bacterial HDAC homologs pre-date the exist-
ence of histones (47). Lysine acetylation of many non-histone 
proteins has been shown to be enhanced by HDAC inhibition, 
for example, with MS-275 (46).
Many transcription factors contain such lysine acetylation 
sites, including cAMP response element-binding protein (CREB), 
whose activity is increased in the presence of TSA (48). CREB 
can be acetylated at three sites, enhancing its transcription factor 
activity, and HDAC8 is known to act on the CREB acetylation 
sites (49). The NF-κB family of transcription factors is also subject 
to posttranslational modification including acetylation as well as 
phosphorylation (50). Myocyte enhancer factor-2 is deacetylated 
by HDAC3, which also acts on the HATs PCAF and p300/CBP 
(51). In addition to transcription factors and HATs, the HDACs 
themselves contain lysine acetylation sites, as do a number of 
structural and regulatory proteins (52). Therefore, it is difficult 
to dissect out the relative contribution of inhibition of histone 
acetylation/deacetylation compared to effects on these other sub-
strates when considering the effects of chemical inhibitors, and 
our findings indicate a complex interplay of signaling pathways 
occurs during infection.
The promoter-reporter analysis showed that inhibitory ele-
m ents located 4,372–2,942 bp upstream from the MMP-1 tran-
scriptional start site decrease promoter activation, since deletion 
of this region enhanced CoMTb-driven promoter activity. The 
area between −2,942 and −2,001  bp contains several critical 
elements required for the induction of gene expression, includ-
ing a putative NF-κB binding site. There is also an AP-1 site at 
−1,950 bp just proximal to the −2,001 bp truncation that might 
be functionally disrupted by this truncation. There is substantial 
evidence that MMP-1 expression is regulated by both NF-κB 
and AP-1 family transcription factors (8, 53, 54), and our data 
support a central role. Similarly, multiple transcription binding 
sites may be important in MMP-3 promoter function. Our chro-
matin immunoprecipitation studies demonstrated that CoMTb 
stimulation leads to increased H3 and H4 acetylation at the 
MMP-1 promoter region. Histone acetylation was an early event 
after CoMTb stimulation occurring concurrently with binding of 
RNA Pol II to the MMP-1 promoter.
In summary, MMP-1 and 3 expression in TB is regulated by 
HDAC and HAT activity. MMP-1 upregulation, as a result of 
epigenetic control, has the potential to drive tissue damage in 
the lung, thereby facilitating spread of infection and develop-
ment of pathology. Chemical inhibition suggests that HDAC 
and HAT activity is necessary for inducible expression of 
MMP-1 and -3 in Mtb-infected macrophages, but that different 
mechanisms operate in NHBEs, where class I HDACs appear 
to act as a brake on collagenase expression. This is a selective 
effect, as MMP-7, which is constitutively expressed in MDMs 
and upregulated by Mtb infection, was unaffected by HDAC and 
HAT inhibition.
The minimal inhibition of MMP responses seen with siRNA 
targeting individual class I HDACs implies that there may be 
some redundancy of function. Increased histone acetylation in 
the MMP-1 promoter region follows Mtb stimulation, favoring 
RNA Pol II binding, and results in upregulation of MMP gene 
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